PubMed Health⌕ Search

Biomedical subjects

F Barrat

Publications and source records attributed to F Barrat.

27 records · Page 2Linked to original sources
PubMed1984

Obliteration of the pelvic space with pedicled omentum after excision of the rectum for cancer.

From 1979 through 1982, removal of the rectum for cancer in 67 patients (50 of whom underwent preoperative radiotherapy) was completed by obliteration of the resulting dead space with pedicled omentum. No complication could be related to the method. After abdominoperineal resection (54 patients), primary healing of the perineal wound was achieved in 77 percent of the patients (85 percent during the last 2 years), and the mean postoperative hospital stay was 22 days. Minor perineal suppuration occurred in 10 patients with a 40 day average time of healing, and major suppuration occurred in 1 patient only with a 3 month time of healing. After the extended Hartmann operation (12 patients), no pelvic abscess was observed and the median hospitalization stay was 19 days. Pelvic filling in the management of patients undergoing rectal excision is an adjunctive procedure that is mainly intended to provide a better postoperative course. It might also facilitate postoperative radiotherapy.

Adenocarcinoma↗
PubMed1983

[Immunocompetence of newborn calves: evaluation of the proliferative response of lymphocytes in vitro to 3 nonspecific mitogens (concanavalin A, phytohemagglutinin, pokeweed mitogen) during the 1st 3 months of life].

A micromethod technique was used to evaluate in vitro sensitivity of the peripheric bovine lymphocytes obtained from a newly born calf, up to 3 months of age to different non-specific mitogens: Phytohemagglutinin (PHA) Concanavaline A (Con A) and Pokeweed Mitogen (PWM). The results obtained show that the calf lymphocytes respond to the 3 mitogens by a considerable cellular proliferation. The blastogenic response was found at various levels during the first 3 months of life, and appeared to stabilize at levels similar to the adult bovine. Highly sensitive variations were noted in the lymphocyte reactivity, notably with PHA and Con A. These results seem to indicate the existence of periods of T cell immunodeficiency, not only during the first few days after birth, but throughout the first months of the calves' life. It may also be indicative of the interest of immunostimulant therapy during this period, which needs further investigation.

Aging↗
PubMedDate not supplied

Effects of polar glycopeptidolipids of Mycobacterium chelonae (pGPL-Mc) on granulomacrophage progenitors.

Effects of polar glycopeptidolipids of Mycobacterium chelonae (pGPL-Mc) in the in vivo stimulation of haematopoietic growth and differentiation of murine bone marrow and spleen cells was investigated in this study. Progenitors were determined with a quantitative cultural analysis of bone marrow and spleen cells in methylcellulose using rmGM-CSF and rmIL3. Injection of pGPL-Mc produced a significant time-related increase in the number of bone marrow and spleen CFUs. pGPL-Mc treatment, in particular, increased the number of bone marrow and splenic CFU-GMs, CFU-Gs and CFU-Ms during and after three intraperitoneal administrations. The greatest myeloid stimulation of bone marrow CFU-GMs, CFU-Gs and CFU-Ms was observed between days 7 and 14, with maximal values on days 12 and 14. Highly significant stimulation of splenic CFU-GMs, CFU-Gs and CFU-Ms was observed between days 7 and 10 with maximal values on day 10, while the initial stimulation of these progenitors was observed starting from day 1 in bone marrow and day 7 in spleen. These effects of pGPL-Mc were associated with an increase in granulocyte, monocyte and thrombocyte counts in the peripheral blood. Granulocyte and monocyte counts remained high up until day 12, while those of thrombocytes were prolonged until day 18. May-Grünwald-Giemsastained colony samples and differential white blood cell counts demonstrated that the granulocyte population is composed almost entirely of neutrophils. pGPL-Mc is therefore a broad-spectrum haematopoietic growth factor with a highly promising application in the reversal of chemotherapy- and/or radiotherapy-induced myelo-suppression.

Animals↗